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Background
It is well recognized that highly active antiretroviral ther-
apy (HAART) can control HIV/AIDS and prolong
patient’s life. However, HAART is associated with drug
toxicity, drug resistant, and patient’s affordability. There-
fore, developing an effective therapeutic vaccine that could
induce HIV-specific immune responses may provide a
solution to reduce the need of antiretroviral therapy. Ade-
novirus based vaccines have been extensively evaluated as
a vaccine vehicle for HIV/AIDS and a variety infectious
diseases, however, it has been a major concern that anti-
Ad5 neutralizing antibodies in general population or after
the first dose of immunization can hinder the its practical
application. The idea of using less prevalent adenovirus
serotypes lack of long-term safety record including onco-
geneicity. Moreover, any adenovirus serotype will inevita-
blely induce neutralizing antibodies after one single use
which render the strategy of using more serotypes
infeasible.
Methods
In this study, we explored a novel “one-size-fits-all” strat-
egy, namely AVIP (Adenoviral Vector Infected PBMC), to
circumvent the attenuated efficacy of Ad-based vaccines
due to anti-Ad immunity.
Results
We demonstrated that this AVIP strategy can elicit SIV-
specific responses in both Ad5-seropositive and Ad5-sero-
negative macaques. Interestingly, comparable SIV-specific
but weaker Ad5-specific responses were elicited in Ad5-
seronegative monkeys received AVIP immunization as
compared to direct injection of Ad5-SIV vaccines. Then a
cohort of Ad5-seropositive SIVmac239-infected monkeys
received AVIP immunization with Ad5 vectors expressing
SIVmac239 Gag, Pol and Env with HAART. After thera-
peutic immunization, SIV-specific response was induced
in vaccinated monkeys whereas a slower responses were
observed in non-vaccinated monkeys. The functional
immunological profiles were also being detected, and we
are also monitoring whether this immunological benefit
would afford a virological benefit.
Conclusion
Our goal is to further develop the AVIP strategy as a
simple but practically effective method for repeated
delivery of Ad5-based vaccines in humans for HIV and
other diseases.
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